Abstract
Patients with brain tumor of malignant have a very poor prognosis because of the aggressive infiltration into normal brain tissue. Successfull treatment of this formidable disease requires targeting therapy for selective killing of tumor cells. Monoclonal antibody (MCA) against a glioma associated antigen, and liposomes are very promising reagents for this purpose. MCA coupled liposomes could bind with glioma cells and lead to a significant increase in the uptake of liposomal contents. A variety of chemotherapeutic agents and biological response modifiers, and also cytokine genes of interferon or tumor necrosis factor were entrapped into the liposomes. We described here the usefulness and possibility of targeting therapy using these drug delivery systems based on results of our experimental and clinical studies.
